Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics.
Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult-to-treat diseases. They discover and develop innovative drugs that enhance tumor-specific immunity.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 6, 2013 | Series A | $20M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
WSR Capital | — | Series A |
Themes Investment Partners | — | Series A |